Aspen looks to expand vaccine production in SA beyond Covid-19
Aspen has capacity to produce 1.35-billion vaccine doses at its Gqeberha facility and is now using less than a quarter of that to help make J&J’s Covid-19 shot
Aspen Pharmacare, SA’s biggest pharmaceutical manufacturer, is in discussions to expand its vaccine production capacity beyond Covid-19 to jabs for other diseases, CEO Stephen Saad said on Thursday.
Aspen has the capacity to produce up to 1.35-billion vaccine doses at its sterile manufacturing facility in Gqeberha, and is currently using less than a quarter of that capacity to help make Johnson & Johnson’s (J&J)’s Covid-19 shot. It aims to ramp up Covid-19 vaccine production from 300-million to 450-million doses a year by February, and to 700-million doses a year by January 2023, but would still have scope to make other kinds of shots, said Saad...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.